Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | AHR | P35869 | 2/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.38 |
| ▸ | PIM1 | P11309 | 2/20 | 0.38 |
| ▸ | FLT3 | P36888 | 2/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.38 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.35 |
| ▸ | S100A4 | P26447 | 1/20 | 0.35 |
| ▸ | METAP2 | P50579 | 3/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.34 |
| ▸ | NOS1 | P29475 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22322700 | 0.92 | ALDH1A1 (0.50) | ALDH1A1CYP2A6MEN1MAPTKMT2A | |
| SCHEMBL192166 | 0.74 | CYP2A6 (0.77) | ALDH1A1CYP2A6MEN1MAPTKMT2A | |
| SCHEMBL29353067 | 0.74 | CYP2A6 (0.77) | ALDH1A1CYP2A6MEN1MAPTKMT2A | |
| SCHEMBL642262 | 0.73 | GRIN2D (0.44) | ALDH1A1CYP2A6MEN1MAPTKMT2A | |
| Hydrochloric Acid SCHEMBL2539013 | 0.71 | GRIN2D (0.43) | ALDH1A1CYP2A6MEN1MAPTKMT2A | |
| SCHEMBL23535686 | 0.71 | KDM4E (0.49) | ALDH1A1MEN1MAPTKMT2AKDM4E | |
| SCHEMBL7967493 | 0.70 | CYP2A6 (0.50) | ALDH1A1CYP2A6MEN1MAPTKMT2A | |
| SCHEMBL30040715 | 0.69 | LCK (0.55) | ALDH1A1MEN1KMT2AKDM4ERPS6KA3 | |
| SCHEMBL148642 | 0.69 | CYP2A6 (0.68) | ALDH1A1CYP2A6MEN1MAPTKMT2A | |
| SCHEMBL17849092 | 0.69 | CYP2A6 (0.68) | ALDH1A1CYP2A6MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250127903-A1 | SUBSTITUTED PIPERIDINE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| US-12048747-B2 | Substituted piperidine Degronimers for Target Protein degradation | C4 THERAPEUTICS, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| US-20220313827-A1 | SUBSTITUTED PIPERIDINE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2022-10-06 | — | — | US | disclosed |
| US-10934275-B2 | IRE1 small molecule inhibitors | CORNELL UNIVERSITY (US) | 2021-03-02 | — | — | US | disclosed |
| EP-3548476-A1 | IRE1 SMALL MOLECULE INHIBITORS | Quentis Therapeutics, Inc. (US) | 2019-10-09 | — | — | EP | disclosed |
| US-20190276434-A1 | IRE1 Small Molecule Inhibitors | QUENTIS THERAPEUTICS, INC. (US) | 2019-09-12 | — | — | US | disclosed |
| EP-3455219-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2019-03-20 | — | — | EP | disclosed |
| US-20190076539-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Theraprutics, Inc. (US) | 2019-03-14 | — | — | US | disclosed |
| WO-2018102751-A1 | IRE1 SMALL MOLECULE INHIBITORS | QUENTIS THERAPEUTICS, INC. (US) | 2018-06-07 | — | — | WO | disclosed |
| WO-2018102751-A1 | IRE1 SMALL MOLECULE INHIBITORS | QUENTIS THERAPEUTICS, INC. (US) | 2018-06-07 | — | — | WO | disclosed |
| WO-2010065674-A9 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-05-31 | — | — | WO | disclosed |
| US-20120122864-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122864-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-8134004-B2 | Substituted N-bicyclicalkyl bicycliccarboxyamide compounds | PFIZER INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-8134004-B2 | Substituted N-bicyclicalkyl bicycliccarboxyamide compounds | PFIZER INC. (US) | 2012-03-13 | — | — | US | disclosed |
| WO-2011149856-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
| WO-2010065674-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| US-20090253740-A1 | SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS | PFIZER INC | 2009-10-08 | — | — | US | disclosed |
| US-20090253740-A1 | SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS | PFIZER INC | 2009-10-08 | — | — | US | disclosed |
| WO-2008007211-A1 | SUBSTITUTED N-BICYCLICALKYL BICYCLIC CARBOXYAMIDE COMPOUNDS | PFIZER JAPAN INC. (JP) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934275-B2 | IRE1 small molecule inhibitors | XBP1, ERN2, ERN1 | ALDH1A1 3482/4885CYP2A6 4061/4885MEN1 3601/4885 |
| US-20090253740-A1 | SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS | OPRL1, CNR1, TRPV1 | ALDH1A1 986/4885CYP2A6 600/4885MEN1 4051/4885 |
| US-20120122864-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | ALDH1A1 3492/4885CYP2A6 2995/4885MEN1 4876/4885 |
| US-20250127903-A1 | SUBSTITUTED PIPERIDINE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, NEDD4 | ALDH1A1 2429/4885CYP2A6 3677/4885MEN1 1735/4885 |
| US-20190276434-A1 | IRE1 Small Molecule Inhibitors | XBP1, ERN2, ERN1 | ALDH1A1 3482/4885CYP2A6 4061/4885MEN1 3601/4885 |
| US-20190076539-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | GCGR, STUB1, GID4 | ALDH1A1 3398/4885CYP2A6 3039/4885MEN1 213/4885 |
| US-20220313827-A1 | SUBSTITUTED PIPERIDINE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, NEDD4 | ALDH1A1 2429/4885CYP2A6 3677/4885MEN1 1735/4885 |
| US-12048747-B2 | Substituted piperidine Degronimers for Target Protein degradation | GID4, RNF5, UBE3C | ALDH1A1 1488/4885CYP2A6 3369/4885MEN1 2187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.